Deciphera Pharmaceuticals... (DCPH)
NASDAQ: DCPH
· Real-Time Price · USD
25.59
0.02 (0.08%)
At close: Jun 10, 2024, 10:00 PM
Deciphera Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Collaboration Arrangement Revenue | 4.28M | 8.53M | 8.76M | 2.63M |
| Collaboration Arrangement Revenue Growth | -49.81% | -2.59% | +233.55% | n/a |
| Product Revenue | 159.07M | n/a | n/a | n/a |
| Product Revenue Growth | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|
| Germany Revenue | 17.96M | 14.3M | 5.91M | 1.5M |
| Germany Revenue Growth | +25.58% | +141.84% | +294.20% | n/a |
| Non-Us Revenue | 19.57M | 28.29M | 81.48M | 38M |
| Non-Us Revenue Growth | -30.82% | -65.28% | +114.41% | n/a |
| United States Revenue | 121.55M | 97.22M | n/a | n/a |
| United States Revenue Growth | +25.03% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 32.78M | 39.15M | 33.25M | 32.61M | 31.45M | 32.2M | 30.03M | 29.63M | 28.32M | 37.15M | 35.53M | 32.83M | 30.75M | 30.07M | 30.14M | 29.93M | 23.94M | 23.74M | 17.98M | 13.16M | 13.24M | 6.47M | 5.26M | 4.45M | 5.03M | 4.68M | 2.43M | 2.24M | 2.07M | 2M | 1.35M |
| Selling, General, and Administrative Revenue Growth | -16.27% | +17.73% | +1.97% | +3.69% | -2.32% | +7.22% | +1.35% | +4.60% | -23.77% | +4.57% | +8.22% | +6.77% | +2.25% | -0.24% | +0.70% | +25.05% | +0.84% | +32.03% | +36.58% | -0.54% | +104.45% | +23.10% | +18.10% | -11.40% | +7.39% | +92.59% | +8.29% | +8.56% | +3.51% | +47.93% | n/a |
| Research and Development Revenue | 57.38M | 58.6M | 62.46M | 58.3M | 54.77M | 48.07M | 47.48M | 44.86M | 47.41M | 74.93M | 66.44M | 59.98M | 55.68M | 52.29M | 49.21M | 46.08M | 51.39M | 46.64M | 40.37M | 34.81M | 35.79M | 27.36M | 20.63M | 17.98M | 16.93M | 15.66M | 9.75M | 8.45M | 5.66M | 6.54M | 4.72M |
| Research and Development Revenue Growth | -2.07% | -6.19% | +7.15% | +6.45% | +13.94% | +1.22% | +5.86% | -5.39% | -36.73% | +12.77% | +10.77% | +7.73% | +6.49% | +6.25% | +6.80% | -10.33% | +10.19% | +15.51% | +15.98% | -2.73% | +30.83% | +32.60% | +14.76% | +6.21% | +8.09% | +60.58% | +15.45% | +49.25% | -13.43% | +38.58% | n/a |